Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including ...

Engineers at the University of Pennsylvania have built a lipid nanoparticle that chemically fuses an IDO-pathway inhibitor with the very lipids that carry IL-12 mRNA into tumors, creating a single ...

The lipid nanoparticles market growth is driven by rising demand for advanced drug delivery systems, increasing adoption of mRNA-based therapeutics and vaccines, and continuous innovations in ...

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

Delray Beach, FL, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The global lipid nanoparticles market is on track to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, driven by advancements in ...

The most common side effects of mRNA vaccines like the COVID-19 shot are well known: soreness, mild fever, and general ...

Lipid nanoparticle formulation has increased over the past two decades. LNPs have proven to be effective nano-based delivery vehicles for cytotoxic chemotherapeutic drugs, nucleic acid therapies and ...

Better mRNA release inside cells boosts vaccine and gene editing performance, enabled by redesigned lipid molecules that grip ...

Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Since then, ...

Global breast cancer incidence continues to rise and researchers have reported that nanoformulations of curcumin may overcome longstanding bioavailability barriers to enhance antitumour efficacy, ...